Company Encyclopedia
View More
name
NCPC
600812.SH
North China Pharmaceutical Company.Ltd engages in the research and development, production, and sales of pharmaceutical products in China and internationally. The company primarily offers anti-infective drugs, biotechnology drugs, cardiovascular cerebrovascular, immunomodulators, and vitamins and health products. It also provides chemical pharmaceuticals; and biological, agricultural, and veterinary drugs. North China Pharmaceutical Company.Ltd was founded in 1992 and is headquartered in Shijiazhuang, China.
3.157 T
600812.SHMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking103/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE3.37%C
    • Profit Margin1.87%C
    • Gross Margin28.09%C
  • Growth ScoreC
    • Revenue YoY0.91%C
    • Net Profit YoY130.58%A
    • Total Assets YoY-0.78%D
    • Net Assets YoY1.04%C
  • Cash ScoreB
    • Cash Flow Margin5351.05%A
    • OCF YoY0.91%C
  • Operating ScoreC
    • Turnover0.45C
  • Debt ScoreD
    • Gearing Ratio69.01%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    NCPC: In the third quarter, the net profit attributable to the parent company was 35.0066 million yuan, an increase of 14.85% year-on-year

    NCPC announced on October 24th that it achieved an operating income of 2.21 billion yuan in the third quarter of 2025, a year-on-year decrease of 5.12%; the net profit attributable to shareholders of the listed company was 35.0066 million yuan, a year-on-year increase of 14.85%; basic earnings per share were 0.02 yuan. In the first three quarters, it achieved an operating income of 7.485 billion yuan, a year-on-year decrease of 1%; the net profit attributable to shareholders of the listed company was 159 million yuan, a year-on-year increase of 54.69%; basic earnings per share were 0.092 yuan

    Zhitong·
    SH
    600812
    +0.17%
    Zhitong·
    SH
    600812
    +0.17%

    NCPC: Wholly-owned subsidiary receives approval notice for the listing application of Cefoperazone chemical raw materials

    NCPC announced that its wholly-owned subsidiary Hebei Huamin Pharmaceutical Co., Ltd. has received the "Approval Notice for the Listing Application of Chemical Raw Materials" for Cefprozil issued by the National Medical Products Administration. Cefprozil is a second-generation cephalosporin antibiotic with advantages such as strong antibacterial activity, resistance to penicillinase, and good clinical efficacy, and can be used to treat bronchitis or other bacterial infections

    Zhitong·
    SH
    600812
    +0.17%
    Zhitong·
    SH
    600812
    +0.17%

    NCPC: Southern Company Obtains Drug Registration Certificate

    NCPC's wholly-owned subsidiary, Southern Company, has obtained the drug registration certificate for injectable imipenem and cilastatin sodium issued by the National Medical Products Administration. This drug is a compound formulation suitable for infections caused by various sensitive bacteria. Southern Company submitted the application in June 2024 and received the registration certificate in September 2025, with a total R&D investment of 5.2243 million yuan. It is expected that sales will reach 2.3 billion yuan in 2024, with a sales volume of approximately 20 million units

    Zhitong·
    SH
    600812
    +0.17%
    Zhitong·
    SH
    600812
    +0.17%

    NCPC has obtained the drug registration certificate for injectable vancomycin hydrochloride (0.5g)

    NCPC recently obtained the drug registration certificate for injectable Vancomycin Hydrochloride (0.5g) approved by the National Medical Products Administration. This certificate indicates that the product meets the basic access conditions for centralized procurement bidding and has an efficacy equivalent to the original research product, further improving the company's product structure in the field of anti-infection

    Zhitong·
    SH
    600812
    +0.17%
    Zhitong·
    SH
    600812
    +0.17%

    NCPC released its semi-annual performance report, with a net profit attributable to the parent company of 123 million yuan, a year-on-year increase of 71.56%

    NCPC released its half-year performance for 2025, with revenue of 5.275 billion yuan, a year-on-year increase of 0.84%; net profit attributable to the parent company of 123 million yuan, a year-on-year increase of 71.56%; net profit excluding non-recurring items of 120 million yuan, a year-on-year increase of 120.69%; basic earnings per share of 0.072 yuan. The company reduced costs and improved profitability through lean management and budget control. The net cash flow from operating activities decreased due to receiving land compensation of 410 million yuan

    Zhitong·
    SH
    600812
    +0.17%
    Zhitong·
    SH
    600812
    +0.17%
    © 2025 Longbridge｜Disclaimer